StockNews.AISignal intelligence
Trevi Therapeutics, Inc. · NASDAQ · Healthcare
Browse public TRVI signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Trevi Therapeutics has launched a public offering of 11.6 million shares at $13 each, aiming to raise approximately $150 million. This funding will likely support the development of Haduvio, its investigational therapy for chronic cough, enhancing their financial position and clinical efforts.
View signal analysisTRVI’s Phase 2b CORAL trial showed significant cough reduction with Haduvio. Top-line results revealed reductions of 60.2%, 53.4%, and 47.9% versus placebo. 65% of patients showed 50% cough reduction using 108 mg BID Haduvio. Statistically significant results were observed in multiple secondary endpoints. Stock declined by 10.45% at $5.83 despite positive data release.
View signal analysisTRVI reported Phase 2a trial results for Haduvio with significant cough reduction. Haduvio achieved 67% reduction in cough frequency; 84% of patients showed improvement. Safety profile was consistent with previous trials; no serious adverse events reported. Stock jumped 40.2% to $6.03 following positive trial results. Topline results for Phase 2b trial expected in early 2025.
View signal analysisTrevi's SSRE analysis confirms no change in CORAL trial sample size. CORAL trial targets idiopathic pulmonary fibrosis patients with chronic cough. Trial enrollment is 75% complete, results expected by first half of 2025. Positive SSRE outcome supports efficacy seen in previous CANAL trial. TRVI stock increased by 71.50% following announcement.
View signal analysis